Is AbbVie bigger than Moderna?

By market capitalization, AbbVie is larger at $388.43B vs Moderna's $20.76B.

Which has better profit margins — AbbVie or Moderna?

AbbVie has higher net profit margins (6.9%) compared to Moderna (-145.2%). Gross and operating margins are compared in the table above.

What sectors do AbbVie and Moderna operate in?

AbbVie operates in the Healthcare sector (Drug Manufacturers - General). Moderna operates in the Healthcare sector (Biotechnology).

How does AbbVie's revenue compare to Moderna's?

AbbVie generates $61.16B in annual revenue (TTM) while Moderna generates $1.94B. AbbVie is the larger company by revenue as of 2026.

AbbVievsModerna

AbbVie vs Moderna: Business Model & Financial Comparison 2026

AbbVie · Healthcare / Drug Manufacturers - General·Moderna · Healthcare / Biotechnology

Financial Comparison

Metric	ABBVAbbVie	MRNAModerna
Market Cap	$388.43B	$20.76B
Revenue (TTM)	$61.16B	$1.94B
Revenue Growth	10.0%	-29.8%
Gross Margin	71.6%	-105.8%
Operating Margin	34.1%	-126.4%
Net Margin	6.9%	-145.2%
Return on Equity	6225.0%	-28.9%
P/E (Trailing)	92.7x	N/A
P/E (Forward)	13.6x	-11.5x
Free Cash Flow	$18.34B	$-1.33B
Cash	$5.26B	$5.80B
Total Debt	$68.40B	$1.30B

Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.

Business Model Comparison

AbbVie

AbbVie Inc. stands as a leading company in Healthcare. Generating $61.16 billion in annual revenue (growing 10.0% year-over-year) and carrying a market capitalization of $410.83 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, AbbVie Inc. continues to execute on a multi-year strategic vision that balances growth investment wit…

Full AbbVie analysis →

Moderna

Moderna, Inc. stands as a leading company in Healthcare. Generating $1.94 billion in annual revenue (growing -29.8% year-over-year) and carrying a market capitalization of $21.26 billion, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, Moderna, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholde…

Full Moderna analysis →

SWOT Analysis Comparison

Strengths

AbbVie

With a market capitalization of $410.83B, AbbVie Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access that sma
AbbVie Inc.'s gross margin of 71.6% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 34.1% demonstrates disciplin
A return on equity of 6225.0% demonstrates that AbbVie Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.

Moderna

Moderna, Inc. holds an established position in the Biotechnology sector, with a track record of serving customers and generating value across its core business activities.
The company's deep expertise in Biotechnology — developed over years of operation — provides meaningful barriers to entry and customer relationship advantages that newer competitors must overcome.

Weaknesses

AbbVie

In the Drug Manufacturers - General sector, larger competitors with greater economies of scale can exert pricing pressure and outspend AbbVie Inc. on marketing, R&D, and distribution — limiting the co
Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strat

Moderna

Year-over-year revenue declined 29.8%, raising questions about demand for Moderna, Inc.'s core offerings and requiring management to articulate a credible recovery path.

Opportunities

AbbVie

AbbVie Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this env
Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for AbbVie
With $5.26B in cash and strong free cash flow generation, AbbVie Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Moderna

Moderna, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment tran
Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Moderna
With $5.80B in cash and strong free cash flow generation, Moderna, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

AbbVie

Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. AbbVie Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scen
Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on AbbVie Inc.'s busin
Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri

Moderna

Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Moderna, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession sc
Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Moderna, Inc.'s bus
Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri

Compare any 2–4 companies with live data

The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.

Open Comparison Tool

AbbVie vs Moderna: FAQ

Is AbbVie bigger than Moderna?: By market capitalization, AbbVie is larger at $388.43B vs Moderna's $20.76B.
Which has better profit margins — AbbVie or Moderna?: AbbVie has higher net profit margins (6.9%) compared to Moderna (-145.2%). Gross and operating margins are compared in the table above.
What sectors do AbbVie and Moderna operate in?: AbbVie operates in the Healthcare sector (Drug Manufacturers - General). Moderna operates in the Healthcare sector (Biotechnology).
How does AbbVie's revenue compare to Moderna's?: AbbVie generates $61.16B in annual revenue (TTM) while Moderna generates $1.94B. AbbVie is the larger company by revenue as of 2026.